Antibodies disrupt bacterial adhesion by ligand mimicry and allosteric interference.

A critical step in infections is the attachment of many microorganisms to host cells using lectins that bind surface glycans, making lectins promising antimicrobial targets. Upon binding mannosylated glycans, FimH, the most studied lectin adhesin of type 1 fimbriae in , undergoes an allosteric transition from an inactive to an active conformation that can act as a catch-bond. Monoclonal antibodies that alter FimH glycan binding in various ways are available, but the mechanisms of these antibodies remain unclear.

Where is ? Implementing citizen science into the biotechnology and environmental science curriculum.

The citizen science project integrates participatory science and community engagement into three courses (ES100-Introduction to Environmental Science, BIOL2700-Environmental Problems, and BIT479/579-High-Throughput Discovery course). Undergraduate students enrolled in ES100 and BIOL2700 collected samples from various locations as part of a class assignment. Students in the BIT479/579 course analyzed the samples using automation and high-throughput molecular biology approaches to reveal the genetic diversity in a portion of a key gene ("gold gene") needed to produce the peptide delftibactin with gold detoxification properties.

Autonomous Dissociation-type Selection for Glycoproteomics Using a Real-Time Library Search.

Tandem mass spectrometry (MS/MS) is the gold standard for intact glycopeptide identification, enabling peptide sequence elucidation and site-specific localization of glycan compositions. Beam-type collisional activation is generally sufficient for glycopeptides, while electron-driven dissociation is crucial for site localization in glycopeptides. Modern glycoproteomic methods often employ multiple dissociation techniques within a single LC-MS/MS analysis, but this approach frequently sacrifices sensitivity when analyzing multiple glycopeptide classes simultaneously.

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.

Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer.